Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
97 hot topic(s) found with the query "Opioid"

DNA test says it can predict opioid addiction risk. Skeptics aren’t so sure.
D Ovalle, Washington Post, March 25, 2024 (Posted: Mar 25, 2024 8AM)

From the article: " Using a swab inside the cheek and a sophisticated computer algorithm, a DNA test recently approved by federal regulators promises to assess genetic risk of opioid addiction. The test’s maker says results give doctors and patients a crucial tool when considering use of the very pain pills that ignited the nation’s opioid crisis. Some geneticists and public health experts say the test relies on unsound science."

A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions.
Yolande Saab et al. Pharmacogenomics J 2023 11 (Posted: Nov 09, 2023 2PM)

From the abstract: "Codeine is metabolized by the CYP2D6 enzyme, and individuals with certain genetic variations of the CYP2D6 gene may metabolize codeine differently, leading to variable efficacy and toxicity. Drug-drug interactions can also affect the metabolism of codeine. A tool to adjust codeine dose based on these factors does not currently exist. Healthcare providers should use their clinical judgment and reference different established dosing guidelines to determine the appropriate dose of codeine for individual patients. The study provides a tool that assists prescribers in adjusting codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions. "

Genome-wide association study on pharmacological outcomes of musculoskeletal pain in UK Biobank.
Song Li et al. Pharmacogenomics J 2023 8 (Posted: Aug 18, 2023 7AM)

To investigate the genetic component of treatment outcome differences, we performed a genome-wide association study (GWAS) in ~23,000 participants with musculoskeletal pain from the UK Biobank. NSAID vs. opioid users were compared as a reflection of the treatment outcome of NSAIDs. We identified one genome-wide significant hit in chromosome 4 (rs549224715, P?=?3.88?×?10-8). Suggestive significant (P?<?1?×?10-6) loci were functionally annotated to 18 target genes, including four genes linked to neuropathic pain processes or musculoskeletal development.

Treating Chronic Pain in Sickle Cell Disease - The Need for a Biopsychosocial Model.
Janet E Childerhose et al. N Engl J Med 2023 4 (15) 1349-1351 (Posted: Apr 13, 2023 6AM)

Chronic pain is the most common complication affecting adults with sickle cell disease (SCD). Pain profoundly affects people’s quality of life, functional ability, and health care utilization. Clinicians are often unsuccessful at addressing chronic pain in SCD, especially among the large number of patients for whom nonopioid analgesics aren’t sufficient and those who have developed opioid tolerance. Why aren’t we doing better?

Can Opioid-Free Anaesthesia Be Personalised? A Narrative Review
J Goff et al, J Per Med, March 10, 2023 (Posted: Mar 10, 2023 3PM)

Opioid death projections with AI-based forecasts using social media language.
Matthew Matero et al. NPJ digital medicine 2023 3 (1) 35 (Posted: Mar 08, 2023 6PM)

Here, we develop and evaluate, TROP (Transformer for Opiod Prediction), a model for community-specific trend projection that uses community-specific social media language along with past opioid-related mortality data to predict future changes in opioid-related deaths. TOP builds on recent advances in sequence modeling, namely transformer networks, to use changes in yearly language on Twitter and past mortality to project the following year’s mortality rates by county. Trained over five years and evaluated over the next two years TROP demonstrated state-of-the-art accuracy in predicting future county-specific opioid trends.

Impact of individual and treatment characteristics on wearable sensor-based digital biomarkers of opioid use.
Chapman Brittany P et al. NPJ digital medicine 2022 8 (1) 123 (Posted: Aug 23, 2022 8AM)

The current manuscript describes a longitudinal, observational study of adult patients receiving opioid analgesics for acute painful conditions. Participants in the study are monitored with a wrist-worn E4 sensor, during which time physiologic parameters (heart rate/variability, electrodermal activity, skin temperature, and accelerometry) are collected continuously. Opioid use events are recorded via electronic medical record and self-report.

A Deep Learning Method to Detect Opioid Prescription and Opioid Use Disorder from Electronic Health Records
A Kashyap et al, MEDRXIV, September 21, 2021 (Posted: Sep 22, 2021 9AM)

As the opioid epidemic continues across the United States, methods are needed to accurately and quickly identify patients at risk for opioid use disorder (OUD). The purpose of this study is to develop two predictive algorithms: one to predict opioid prescription and one to predict OUD. Materials and Methods: We developed an informatics algorithm that trains two deep learning models over patient EHRs using the MIMIC-III database. We utilize both the structured and unstructured parts of the EHR and show that it is possible to predict both of these challenging outcomes

Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests
G Zhu et al, Pharmacogenomics Journal, September 2021 (Posted: Sep 04, 2021 10AM)

Urine drug testing (UDT) is a tool for monitoring drug use, including oxycodone. While variation in cytochrome P450 (CYP) genes is known to alter oxycodone metabolism, its impact on UDT results of oxycodone and its metabolites has not been well-studied. Here, multivariate analysis was performed on retrospective UDT results of 90,379 specimens collected from 14,684 genotyped patients prescribed oxycodone. Genetic variation in CYP2D6 and CYP2C19 had a significant impact on oxymorphone/oxycodone ratios, with a 6.9-fold difference between CYP2D6 ultrarapid metabolizers (UMs) and poor metabolizers.

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)
M Matic et al, The Pharmacogenomics Journal, July 15, 2021 (Posted: Jul 16, 2021 7AM)

The current Dutch Pharmacogenetics Working Group (DPWG) guideline, describes the gene–drug interaction between CYP2D6 and the opioids codeine, tramadol and oxycodone. CYP2D6 genotype is translated into normal metaboliser (NM), intermediate metaboliser (IM), poor metaboliser (PM) or ultra-rapid metaboliser (UM).

Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
AL Elchynsky et al, The PGx journal, June 3, 2021 (Posted: Jun 04, 2021 11AM)

We aimed to determine the potential value of panel-based pharmacogenetic (PGx) testing in patients with chronic pain or gastroesophageal reflux disease (GERD) who underwent single-gene PGx testing to guide opioid or proton pump inhibitor (PPI) therapy, respectively. Of 448 patients included (chronic pain, n?=?337; GERD, n?=?111), mean age was 57 years, 68% were female, and 73% were white. Excluding opiates for the pain cohort and PPIs for the GERD cohort, 76.6% of patients with pain and 71.2% with GERD were prescribed at least one additional medication with a high level of PGx evidence, most commonly ondansetron or selective serotonin reuptake inhibitors.

Big data, artificial intelligence, and the opioid crisis
Lancet Digital Health editorial, June 1, 2021 (Posted: May 26, 2021 6AM)

Big data and artificial intelligence can help to target preventive measures (eg, addressing comorbidities and socioeconomic inequalities) to reduce future risks of opioid misuse. Community-level modelling can forecast the number of fatal overdoses that could be avoided through wider availability of key treatments. But model explainability and integration of individual-level factors— clinical and social—are crucial to remove barriers and ensure prevention and treatment efforts are accessible to all.

Identifying Opioid Withdrawal Using Wearable Biosensors.
Kulman Ethan et al. Proceedings of the ... Annual Hawaii International Conference on System Sciences. Annual Hawaii International Conference on System Sciences 2021 Jan 543583-3592 (Posted: Feb 16, 2021 9AM)

Wearable biosensors can be used to monitor opioid use, a problem of dire societal consequence given the current opioid epidemic in the US. Such surveillance can prompt interventions that promote behavioral change. Prior work has focused on the use of wearable biosensor data to detect opioid use. In this work, we present a method that uses machine learning to identify opioid withdrawal using data collected with a wearable biosensor.

Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders A Multivariable Mendelian Randomization Analysis
DB Rosoff et al, JAMA Psychiatry, November 11, 2020 (Posted: Nov 11, 2020 11AM)

The findings of this mendelian randomization analysis suggest evidence for potential causal associations between the genetic liability for increased prescription opioid use and the risk for major depression. While replication studies are necessary, these findings may inform prevention and intervention strategies.

A review of the existing literature on buprenorphine pharmacogenomics
CW Meaden et al, Pharmacogenomics Journal, November 5, 2020 (Posted: Nov 07, 2020 10AM)

Variations of the pharmacokinetic gene for CYP3A4 showed that the ultrarapid metabolizer phenotype required higher doses of buprenorphine. Genotyping of patients may allow us to appropriately tailor buprenorphine therapy to individual patients and lead to improved patient outcomes; however, further research on the pharmacogenomics of buprenorphine is needed.

Association of OPRM1 Functional Coding Variant With Opioid Use Disorder-A Genome-Wide Association Study
H Zhou et al, JAMA Psychiatry, June 3, 2020 (Posted: Jun 04, 2020 7AM)

Meta-analysis of 10?544 individuals of European ancestry with opioid use disorder and 72?163 opioid-exposed control individuals identified OPRM1 functional variant rs1799971 as associated with opioid use disorder, with replication in 2 independent samples; no significant associations were detected for individuals of African ancestry

Genetic polymorphisms in the opioid receptor delta 1 (OPRD1) gene are associated with methadone dose in methadone maintenance treatment for heroin dependence
CP Fang et al, J Hum Genetics, January 2020 (Posted: Jan 13, 2020 9AM)

The Detection of Opioid Misuse and Heroin Use From Paramedic Response Documentation: Machine Learning for Improved Surveillance.
Prieto José Tomás et al. Journal of medical Internet research 2020 Jan 22(1) e15645 (Posted: Jan 08, 2020 8AM)

Timely, precise, and localized surveillance of nonfatal events is needed to improve response and prevention of opioid-related problems in an evolving opioid crisis in the United States. Machine learning approach can refine surveillance to improve first-responder and public health responses toward prevention of overdoses and other opioid-related problems.

Effort To Control Opioids In An ER Leaves Some Sickle Cell Patients In Pain
S Whitehead, NPR, January 2, 2020 (Posted: Jan 03, 2020 9AM)

People with sickle cell disease aren't fueling the opioid problem, One study published in 2018 found that opioid use has remained stable among sickle cell patients over time, even as opioid use as risen in the U.S. generally. If anything, individuals with sickle cell disease have really been caught in the crossfire when it comes to this opioid epidemic.

Current status of opioid addiction treatment and related preclinical research.
Kreek M J et al. Science advances 2019 Oct (10) eaax9140 (Posted: Dec 09, 2019 9AM)

Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.
Kelty Erin et al. CNS drugs 2019 Nov (11) 1113-1120 (Posted: Dec 09, 2019 9AM)

A range of risk factors have been associated with NOWS, including features of neonatal drug exposure, maternal and neonatal characteristics, aspects of labor and delivery, and genetics. Increased length of gestation and higher birth weight were consistently associated with an increased risk of NOWS.

Using machine learning to predict opioid misuse among U.S. adolescents.
Han Dae-Hee et al. Preventive medicine 2019 Nov 130105886 (Posted: Nov 13, 2019 8AM)

This study evaluated prediction performance of three different machine learning (ML) techniques in predicting opioid misuse among U.S. adolescents. Data were drawn from the 2015-2017 National Survey on Drug Use and Health (N=?41,579 adolescents, ages 12-17 years) and analyzed in 2019. Prediction models were developed using three ML algorithms.

Machine Learning and Natural Language Processing for Geolocation-Centric Monitoring and Characterization of Opioid-Related Social Media Chatter
A Sarker et al, JAMA Network Open, November 6, 2019 (Posted: Nov 07, 2019 8AM)

In this cross-sectional, population-based study of 9006 social media posts, automatic processing of social media data, combined with geospatial and temporal information, may provide close to real-time insights into the status and trajectory of the opioid epidemic.

GWAS including 82,707 subjects identifies functional coding variant in OPRM1 gene associated with opioid use disorder
H Zhou et al, MedRXIV, September 18, 2019 (Posted: Sep 19, 2019 9AM)

Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium
R Polimanti et al, BioRXIV, September 11, 2019 (Posted: Sep 13, 2019 10AM)

The imperative of clinical and molecular research on neonatal opioid withdrawal syndrome.
Metpally Raghu P et al. Molecular psychiatry 2019 Sep (Posted: Sep 12, 2019 7AM)

Using Telemedicine to Treat Opioid Use Disorder in Rural Areas
R Rubin, JAMA< August 28, 2019 (Posted: Aug 29, 2019 8AM)

Some academic medical centers, federal agencies, and for-profit companies have begun to treat opioid use disorder via telemedicine. In most cases, patients connect with physicians or other waived health care professionals on computers at clinics or OUD treatment centers.

Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic A Qualitative Study
CB Sinha, JAMA Network Open, May 24, 2019 (Posted: May 27, 2019 5PM)

Association Between Parental Medical Claims for Opioid Prescriptions and Risk of Suicide Attempt by Their Children.
Brent David A et al. JAMA psychiatry 2019 May (Posted: May 23, 2019 8AM)

Partnering Together to Prevent Overdose
CDC, April 22, 2019 Brand (Posted: Apr 23, 2019 1PM)

Applications of machine learning in addiction studies: A systematic review.
Mak Kwok Kei et al. Psychiatry research 2019 Mar 53-60 (Posted: Mar 20, 2019 8AM)

Predicting opioid dependence from electronic health records with machine learning.
Ellis Randall J et al. BioData mining 2019 3 (Posted: Feb 14, 2019 9AM)

Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits
J Li et al, Pharmacogenomics Journal, February 14, 2019 (Posted: Feb 14, 2019 8AM)

Detecting opioid overdoses with smartphones
H Stower, Nature Medicine, February 6, 2019 (Posted: Feb 08, 2019 9AM)

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Smith D Max et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Jan (Posted: Jan 25, 2019 9AM)

Pain polymorphisms and opioids: An evidence based review.
Vieira Cláudia Margarida Pereira et al. Molecular medicine reports 2018 Dec (Posted: Jan 01, 2019 1PM)

Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients.
Muriel Javier et al. Basic & clinical pharmacology & toxicology 2018 Oct (Posted: Dec 19, 2018 10AM)

Predicting those at risk for opioid abuse
M McFadden, November 1,2018 (Posted: Nov 04, 2018 0PM)

Gutted about opioids- The microbiome may have an influence on addiction
W Yan, Nature Medicine, October 30, 2018 (Posted: Oct 30, 2018 0PM)

PharmGKB oxycodone pathway published in Pharmacogenetics and Genomics
PHRMGKB, October 2018 (Posted: Oct 28, 2018 8AM)

Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population.
Wang Ruey-Yun et al. PloS one 2018 13(7) e0201408 (Posted: Aug 01, 2018 10AM)

Single Nucleotide Polymorphisms in TAOK3 Are Associated with High Opioid Requirement for Pain Management in Patients with Advanced Cancer Admitted to a Tertiary Palliative Care Unit.
Gutteridge Timothy et al. Journal of pain and symptom management 2018 Jul (Posted: Jul 25, 2018 8AM)

An Ambitious Research Plan to Help Solve the Opioid Crisis
Brand (Posted: Jun 12, 2018 10AM)

The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review.
Oueslati Bilel et al. Pharmacogenomics 2018 May (Posted: May 23, 2018 9AM)

Pharmacogenetics of Opioid Use Disorder Treatment.
Crist Richard C et al. CNS drugs 2018 Apr (Posted: Apr 17, 2018 9PM)

Confronting the Opioid Epidemic
Brand (Posted: Apr 17, 2018 6PM)

NIH launches HEAL Initiative, doubles funding to accelerate scientific solutions to stem national opioid epidemic
NIH News Release, Apr 4, 2018 (Posted: Apr 04, 2018 9AM)

Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl.
Lloyd Renae A et al. Pain medicine (Malden, Mass.) 2017 Dec (12) 2369-2387 (Posted: Apr 02, 2018 1PM)

New Gene Variant Robustly Linked to Opioid Addiction
M Brooks, Medscape, Mar 2018 (Posted: Mar 09, 2018 9AM)

Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad Taha et al. Biochemical pharmacology 2018 Feb (Posted: Mar 06, 2018 7PM)

Opioid Overdoses Treated in Emergency Departments
CDC Vital Signs, Mar 6, 2018 Brand (Posted: Mar 06, 2018 2PM)

A brief review of the genetics and pharmacogenetics of opioid use disorders.
Berrettini Wade et al. Dialogues in clinical neuroscience 2017 Sep (3) 229-236 (Posted: Feb 07, 2018 11AM)

CDC Rx Awareness Campaign
Brand (Posted: Feb 07, 2018 11AM)

Genome Culture: Genetic Testing for Susceptibility to Opioid Addiction Is a Risky Business
L Hercher, Genome Magazine, Jan 25, 2018 (Posted: Jan 29, 2018 3PM)

Pharmacogenetics of Methadone Response.
Fonseca Francina et al. Molecular diagnosis & therapy 2017 Nov (Posted: Dec 17, 2017 7PM)

Genetic study defies 'one-size-fits-all' approach to prescribing opioids for chronic pain
Medical Xpress, Dec 13, 2017 (Posted: Dec 17, 2017 7PM)

From fighting cancer to opioid addiction: Genetics matter with medications
Mayo Clinic, Oct 9, 2017 (Posted: Oct 10, 2017 10AM)

Opioid crisis adds to pain of sickle cell patients
Brand (Posted: Sep 15, 2017 3PM)

Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region — United States, 2006–2015
JK O'Donnell et al, MMWR, Sept 1, 2017 (Posted: Sep 01, 2017 10AM)

A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.
Moretti M E et al. The pharmacogenomics journal 2017 Jul (Posted: Jul 19, 2017 8AM)

Public-Private Initiative to Address the Opioid Crisis
NIH initiative, 2017 Brand (Posted: Jul 17, 2017 8PM)

Road to Recovery: New personalized treatments and technologies are helping people free themselves from opioid addiction.
Genome Magazine, Summer 2017 (Posted: Jul 15, 2017 10AM)

New Data on Opioid Use and Prescribing in the United States.
A Schuchat el, JAMA, July 11, 2017 (Posted: Jul 11, 2017 11AM)

Opioid Prescribing- Where you live matters
CDC Vital Signs, July 2017 Brand (Posted: Jul 06, 2017 5PM)

Fighting Opioid Overdose
Brand (Posted: Jun 23, 2017 6PM)

All Scientific Hands on Deck to End the Opioid Crisis
N Volkov and F Collins, NIH Blog, May 31, 2017 Brand (Posted: Jun 01, 2017 8AM)

Pharmacogenomics for personalized pain medicine.
Ko Tai-Ming et al. Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists 2016 Mar (1) 24-30 (Posted: Jun 01, 2017 8AM)

Codeine Therapy and CYP2D6 Genotype
L Dean, NCBI 2012 Brand (Posted: Jun 01, 2017 8AM)

Tramadol Therapy and CYP2D6 Genotype
L Dean, NCBI 2015 Brand (Posted: Jun 01, 2017 8AM)

The CDC Guideline on Opioid Prescribing- Rising to the Challenge
Y. Olson, JAMA, March, 2016 (Posted: Mar 28, 2016 3PM)

The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review.
Baber Marta et al. Pharmacogenomics 2016 Jan (1) 75-93 (Posted: Mar 15, 2016 2PM)

Opioid metabolism and clinical aspects.
Mercadante Sebastiano et al. European journal of pharmacology 2015 Dec 71-8 (Posted: Mar 15, 2016 2PM)

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.
Bell Gillian C et al. Cancer control : journal of the Moffitt Cancer Center 2015 Oct (4) 426-32 (Posted: Dec 19, 2015 10AM)

Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014
MMWR, December 18, 2015 (Posted: Dec 19, 2015 10AM)

Clues to opioid abuse from state prescription drug monitoring programs
Brand (Posted: Oct 16, 2015 2PM)

Addressing the Opioid Epidemic
LS Nelson et al, JAMA October 13, 2015 (Posted: Oct 13, 2015 11AM)

Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013
B Han et al, JAMA< October 13, 2015 (Posted: Oct 13, 2015 11AM)

The genetic influences on oxycodone response characteristics in human experimental pain.
Olesen Anne E et al. Fundam Clin Pharmacol 2015 Aug (4) 417-425 (Posted: Jul 08, 2015 9AM)

Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction.
Reyes-Gibby Cielito C et al. BMC Syst Biol 2015 25 (Posted: Jul 08, 2015 9AM)

Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.
Patriquin Michelle A et al. Psychiatr. Genet. 2015 Jul 2. (Posted: Jul 08, 2015 9AM)

Genetic Variants Influencing Patient Response to Opioid Therapy.
Tadje Marsha et al. Oncol Nurs Forum 2015 Jul 1. (4) 420-422 (Posted: Jul 08, 2015 9AM)

Pharmacogenomics and Opioid Analgesics: Clinical Implications.
Yiannakopoulou Eugenia et al. Int J Genomics 2015 368979 (Posted: Jul 07, 2015 3PM)

The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis.
Ren Zhen-Yu et al. Pain Physician 2015 Mar-Apr (2) 131-52 (Posted: May 13, 2015 4PM)

Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics.
Sadhasivam S et al. Pharmacogenomics J. 2015 Apr (2) 119-26 (Posted: Mar 31, 2015 3PM)

Pharmacogenetics of opioid response.
Somogyi A A et al. Clin. Pharmacol. Ther. 2015 Feb (2) 125-7 (Posted: Mar 31, 2015 3PM)

High-throughput gene expression profiling of opioid-induced alterations in discrete brain areas.
Korostynski Michal et al. Methods Mol. Biol. 2015 65-76 (Posted: Mar 31, 2015 3PM)

Mu opioid receptor gene: new point mutations in opioid addicts.
Dinarvand Amin et al. Basic Clin Neurosci 2014 (1) 18-21 (Posted: Mar 31, 2015 3PM)

MicroRNAs: Emerging Role in the Endogenous µ Opioid System.
Barbierato Massmo et al. CNS Neurol Disord Drug Targets 2015 (2) 239-50 (Posted: Mar 31, 2015 3PM)

Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Linares Oscar A et al. Clin J Pain 2015 Jan 23. (Posted: Mar 31, 2015 3PM)

Addressing prescription opioid overdose: data support a comprehensive policy approach.
Jones Christopher M et al. JAMA 2014 Nov 5. (17) 1733-4 (Posted: Mar 31, 2015 3PM)

Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome.
Wachman Elisha M et al. J. Pediatr. 2014 Sep (3) 472-8 (Posted: Mar 10, 2015 4PM)

Opioid prescription claims among women of reproductive age--United States, 2008-2012.
Ailes Elizabeth C et al. MMWR Morb. Mortal. Wkly. Rep. 2015 Jan 23. (2) 37-41 (Posted: Mar 10, 2015 4PM)

CDC Information Fact Sheet: Prescription Drug Overdose in the United States
Brand (Posted: Feb 25, 2015 0PM)

CDC Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013
MMWR, July 7, 2015 Brand (Posted: Feb 25, 2015 0PM)

Today's Heroin Epidemic More people at risk, multiple drugs abused
Brand (Posted: Feb 25, 2015 0PM)

Opioid pain medications used early in pregnancy might increase risk of some birth defects
Brand (Posted: Feb 25, 2015 0PM)

Managing Chronic Pain: Opioids Are Often Not the Answer
January 27, 2015 by Dr. Francis Collins, NIH Director Brand (Posted: Feb 13, 2015 9AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP